A panel of six autoantibodies may provide a specific and reasonably sensitive early test for lung cancer, a multinational study has suggested.
Serum samples were obtained from three groups of patients after they were diagnosed but before any treatment. Levels of antibodies against p53, NY-ESO-1, CAGE, GBU4-5, Annexin 1 and SOX2 had a sensitivity of almost 40% and a specificity of about 90% for lung cancer, regardless of the cancer subtype.
The three groups comprised 145 American and Russian patients with stage I or II cancer, 241 German patients treated at a single centre, and 269 patients in a validation cohort. Every case was matched by gender, age and smoking history to a control without cancer.
Although the latent period...
This site is intended for Registered Medical Practitioners.
To make the most of Oncology Update, you need to be logged in.